(Q38268951)

1 September 2017

title

A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy (English)

1 reference

progressive multifocal leukoencephalopathy

1 September 2017

main subject

0 references

author name string

Salim Chahin

series ordinal

1

1 reference

1 September 2017

Joseph R Berger

series ordinal

2

1 reference

1 September 2017

publication date

18 November 2014

1 reference

1 September 2017

published in

Journal of NeuroVirology

1 reference

1 September 2017

volume

21

1 reference

1 September 2017

issue

6

1 reference

1 September 2017

page(s)

623-631

1 reference

https://scigraph.springernature.com/pub.10.1007/s13365-014-0303-1

1 September 2017

exact match

0 references

cites work

anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy and newer biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

JC virus antibody status underestimates infection rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A review of the current use of rituximab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Alemtuzumab induction in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Current concepts and review of efalizumab in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Immune cell migration in inflammation: present and future therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

How does infliximab work in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Characterization of JC human polyomavirus infection in a Portuguese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Mechanism of action of mycophenolate mofetil

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

21 January 2018

12 December 2020

Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

The discovery of natalizumab, a potent therapeutic for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

α4Integrins as Therapeutic Targets in Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13365-014-0303-1

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

21 January 2018

1 reference

12 December 2020

PML in a patient treated with fumaric acid

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.

1 reference

12 December 2020

Natalizumab risk stratification: role of a two- step anti-JCV antibody assay

1 reference

12 December 2020

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin

1 reference

12 December 2020

The status of biologic therapies in the treatment of moderate to severe psoriasis

1 reference

12 December 2020

The pathogenesis of progressive multifocal leukoencephalopathy

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia

1 reference

12 December 2020

TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques

1 reference

12 December 2020

Mycophenolate mofetil: An update

1 reference

12 December 2020

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

1 reference

12 December 2020

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP)

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

1 reference

12 December 2020

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

10.1007/S13365-014-0303-1

Identifiers

DOI

1 reference

1 September 2017

1 reference